🔍

MEDANTA - Global Health

📊 NSE: MEDANTA 🏢 Healthcare 📅 Last Updated: 12/13/2025 22:23

📢 Recent Corporate Announcements

Medanta to Acquire 80-Bed Cancer Hospital in Indore for Rs 30 Crore

🟢 POSITIVE ⭐ 8/10

EXPANSION 📅 27 Apr 2026, 03:09 PM

Global Health Limited (Medanta) has signed a Business Transfer Agreement to take over an 80-bed cancer hospital in Indore for a consideration of Rs 30 crore. The facility is strategically located just 500 meters from Medanta's existing 175-bed multi-specialty hospital, allowing for significant operational synergies. This acquisition enables Medanta to launch a comprehensive oncology program in Indore, filling a previous gap in its specialty offerings. The move strengthens the company's footprint in Central India and is expected to optimize capacity utilization across its Indore campus.

Acquisition of an 80-bed newly-built Cancer Care Hospital in Indore for Rs 30 crore
Facility is located 500 meters from the existing 175-bed Medanta Indore hospital
Acquisition includes the transfer of business as a going concern and assignment of a long-term lease
Enables the launch of a comprehensive oncology program to enhance high-margin specialty offerings
Medanta's total operational network reached 3,579 installed beds as of December 31, 2025

💡 Investors should view this as a strategic, low-cost expansion that enhances Medanta's service mix and regional market share. Monitor the impact on Average Revenue Per Occupied Bed (ARPOB) as the high-margin oncology services scale up.

Medanta to Acquire 79-Bed Cancer Hospital in Indore for ₹30 Crores

🟢 POSITIVE ⭐ 8/10

M&A 📅 27 Apr 2026, 02:44 PM

Global Health Limited (Medanta) has approved the acquisition of a 79-bedded oncology-focused hospital in Indore through a Business Transfer Agreement (BTA). The facility is strategically located just 500 meters from Medanta's existing Indore hospital, which is expected to drive significant operational synergies and fill a specialty gap in oncology. The acquisition cost is ₹30 crores, to be funded via internal accruals and debt, with completion expected by September 2026. This move expands Medanta's total capacity from its current base of 3,579 beds.

Acquisition of a 79-bed specialized cancer care facility in Indore for ₹30 crores
Target facility is located 500 meters from the existing Medanta Indore hospital, enabling high synergy
Expands Medanta's total network capacity from 3,579 beds as of March 2026
Target hospital reported a turnover of ₹19.9 million for the financial year 2024-25
Transaction to be completed by September 30, 2026, funded through internal accruals and debt

💡 Investors should look favorably on this acquisition as it strengthens Medanta's regional dominance in Indore at a reasonable valuation. Monitor the post-acquisition integration and the impact on oncology-driven ARPOB (Average Revenue Per Occupied Bed).

Medanta to Acquire 79-Bed Cancer Hospital in Indore for Rs 30 Crore

🟢 POSITIVE ⭐ 8/10

M&A 📅 27 Apr 2026, 02:41 PM

Global Health Limited (Medanta) has entered into a Business Transfer Agreement to acquire a 79-bedded specialized cancer care hospital in Indore for Rs 30 crore. The facility is strategically located just 500 meters from Medanta's existing Indore hospital, which will enable significant operational synergies and fill a specialty gap in oncology. The acquisition will be funded through a mix of internal accruals and debt, with a target completion date before September 30, 2026. This move expands Medanta's total capacity, which stood at 3,579 beds as of March 31, 2026.

Acquisition of a 79-bedded cancer care hospital in Indore for a cash consideration of Rs 30 crore.
Target facility is located 500 meters from the existing Medanta Indore facility, ensuring high synergy potential.
The target hospital reported a turnover of Rs 19.9 million for the financial year 2024-25.
Medanta's total network capacity reaches 3,658 beds following this acquisition (from 3,579 beds).
Transaction expected to close by September 30, 2026, funded via internal accruals and debt.

💡 Investors should look favorably on this acquisition as it strengthens Medanta's regional dominance in Indore at a relatively low cost per bed. Monitor the integration process and the subsequent improvement in the acquired facility's turnover and margins.

Medanta to Meet Permodalan Nasional Berhad (PNB) on March 31, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 26 Mar 2026, 04:28 PM

Global Health Limited (Medanta) has announced a one-on-one virtual meeting with Permodalan Nasional Berhad (PNB), Malaysia, scheduled for March 31, 2026. This meeting is part of the company's routine engagement with institutional investors to discuss business updates. The company has explicitly stated that no unpublished price sensitive information (UPSI) will be shared during the interaction. Such disclosures are mandatory under SEBI Listing Obligations and Disclosure Requirements to ensure transparency.

One-on-one virtual meeting scheduled with Permodalan Nasional Berhad (PNB) on March 31, 2026.
The meeting is a routine institutional investor interaction under SEBI Regulation 30.
Company confirms that no unpublished price sensitive information (UPSI) will be disclosed.
The schedule is subject to change based on unforeseen circumstances from either party.

💡 This is a routine regulatory filing with no immediate impact on stock fundamentals. Investors should watch for any subsequent investor presentations or transcripts that might be uploaded after the meeting.

Medanta to Expand in UP with 400-Bed Varanasi Hospital and Rs 322 Cr Medical College

🟢 POSITIVE ⭐ 8/10

EXPANSION 📅 25 Mar 2026, 03:57 PM

Global Health Limited (Medanta) has announced a significant expansion in Uttar Pradesh with a new 400-bed multi-specialty hospital in Varanasi. The project will follow a build-to-suit lease model where Medanta invests approximately Rs. 550 crores in medical equipment and interiors, while a partner develops the civil structure. Additionally, the company will invest Rs. 322 crores to establish a medical college directly under its corporate entity, leveraging revised NMC regulations. These projects, expected to be completed within four years, will strengthen Medanta's presence in the underserved Eastern UP market.

Planned 400-bed multi-specialty hospital in Varanasi with an estimated investment of Rs. 550 crores by Medanta.
Approval for a new medical college with a project cost of Rs. 322 crores to be funded via internal accruals or debt.
Varanasi project to be executed via a lease agreement with Shripal Hospitality, reducing initial civil construction capex.
Total bed capacity in Uttar Pradesh to reach approximately 1,900 beds across Lucknow, Noida, and Varanasi.
Project completion for the Varanasi hospital is targeted within a 4-year timeframe.

💡 Investors should look favorably on this expansion as it targets a high-demand, underserved region using a capital-efficient lease model for the hospital building. Monitor the company's debt-to-equity ratio as it undertakes a combined investment of over Rs. 870 crores for these new ventures.

Medanta to Add 400-Bed Varanasi Hospital and ₹322 Cr Medical College in UP Expansion

🟢 POSITIVE ⭐ 8/10

EXPANSION 📅 25 Mar 2026, 03:50 PM

Global Health Limited (Medanta) has announced a major expansion in Uttar Pradesh, including a new 400-bed multi-specialty hospital in Varanasi and a dedicated medical college. The Varanasi hospital will be developed via a build-to-suit lease model with an estimated investment of ₹550 crores by Medanta for equipment and fit-outs, expected to be completed in 4 years. Additionally, the company will invest ₹322 crores to establish a medical college, which will now be held directly by the company instead of a subsidiary. This move strengthens Medanta's presence in North India, bringing its total planned capacity in Uttar Pradesh to approximately 1,900 beds.

Planned 400+ bed multi-specialty hospital in Varanasi via a build-to-suit lease agreement.
Estimated investment of ₹550 crores for Varanasi facility interiors, MEP, and medical equipment.
Approval for a medical college with a total project cost of ₹322 crores funded by internal accruals or debt.
Varanasi hospital construction expected to be completed within a 4-year timeline.
Expansion will increase Medanta's total Uttar Pradesh capacity to approximately 1,900 beds.

💡 This is a positive long-term development as Medanta targets the underserved Eastern UP market using an asset-light building model. Investors should monitor the execution progress and the impact of the ₹872 crore total planned capex on the company's balance sheet.

Medanta to Invest ₹872 Cr for 400-Bed Varanasi Hospital and New Medical College

🟢 POSITIVE ⭐ 8/10

EXPANSION 📅 25 Mar 2026, 03:49 PM

Global Health Limited (Medanta) has announced a major expansion strategy involving a total investment of approximately ₹872 crores. The company will establish a 400-bed multi-specialty hospital in Varanasi through a ₹550 crore investment under a build-to-suit lease model. Additionally, Medanta is entering the medical education sector by setting up a medical college with an approved project cost of ₹322 crores. These projects, funded via internal accruals and debt, aim to solidify the company's dominant position in the Uttar Pradesh healthcare market.

Approved ₹550 crore investment for a new 400-bed super-specialty hospital in Varanasi to be completed within 4 years.
Allocated ₹322 crore for establishing a Medical College to create a captive pipeline of skilled medical professionals.
The Varanasi facility will increase Medanta's total bed capacity in Uttar Pradesh to approximately 1,900 beds.
Expansion follows revised NMC regulations allowing companies to directly own and operate medical colleges.
Current operational capacity stands at 3,579 beds across Gurugram, Indore, Ranchi, Lucknow, Patna, and Noida.

💡 Investors should view this as a strong long-term growth move that addresses the underserved healthcare market in Eastern UP. While the 4-year gestation period for the hospital requires patience, the entry into medical education provides a strategic advantage for talent acquisition.

Medanta (Global Health) Grants 10,000 ESOPs at Exercise Price of Rs. 776

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 24 Mar 2026, 02:19 PM

Global Health Limited (Medanta) has approved the grant of 10,000 stock options to a single employee under its 2024 Long Term Share Based Incentive Plan. The options are issued at an exercise price of Rs. 776 per share, with each option convertible into one equity share of Rs. 2 face value. The vesting period for these options is set for a maximum of five years, designed to retain and motivate key talent. This is a routine corporate action with minimal impact on the company's overall share capital.

Grant of 10,000 ESOPs to one employee under the GHL LTIP 2024 Plan
Exercise price fixed at Rs. 776 per equity share
Vesting period extends up to a maximum of 5 years from the grant date
Exercise period is 3 years from the date of the last vesting installment
Each option results in the allotment of one equity share of Rs. 2 face value

💡 No action is required as the grant size is negligible and will not lead to any meaningful equity dilution. Investors should focus on the company's core healthcare operations and hospital expansion metrics.

Medanta to Close Trading Window from April 1, 2026, Ahead of Q4 and FY26 Results

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 24 Mar 2026, 01:24 PM

Global Health Limited (Medanta) has announced the closure of its trading window for all designated persons starting April 1, 2026. This action is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, regarding the upcoming financial disclosures. The window will remain closed until 48 hours after the declaration of the audited financial results for the fourth quarter and the full financial year ending March 31, 2026. This is a standard regulatory procedure for listed companies in India.

Trading window closure effective from April 1, 2026
Closure is for the purpose of Q4 and FY ended March 31, 2026 audited results
Window to reopen 48 hours after the official results announcement
Filing made in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015

💡 No action is required as this is a routine regulatory filing. Investors should look out for the specific date of the Q4 FY26 earnings call to evaluate the company's performance.

Medanta (Global Health) Schedules Investor Meetings in Gurugram and Lucknow on March 24-25

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 18 Mar 2026, 05:50 PM

Global Health Limited (Medanta) has announced a schedule for group meetings with institutional investors and analysts on March 24 and 25, 2026. These meetings, organized by ICICI Securities, will be held in person in Gurugram and Lucknow. The company has explicitly stated that no unpublished price sensitive information (UPSI) will be shared during these sessions. Such meetings are standard practice for maintaining transparency and providing business updates to the investment community.

Meetings scheduled for March 24, 2026, in Gurugram and March 25, 2026, in Lucknow.
The interactions are organized by ICICI Securities Limited as group meetings.
The company confirmed that no Unpublished Price Sensitive Information (UPSI) will be disclosed.
The meetings are subject to change based on unforeseen circumstances from either party.

💡 No immediate action is required as this is a routine disclosure. Investors should monitor for any post-meeting presentations or transcripts that may provide qualitative insights into Medanta's regional growth strategies.

Medanta Shareholders Approve Key Director Appointments with Over 99% Majority

🟢 POSITIVE ⭐ 6/10

MANAGEMENT 📅 14 Mar 2026, 05:28 PM

Global Health Limited (Medanta) has successfully passed three resolutions via postal ballot with overwhelming shareholder support. Dr. Ravi Gupta and Mr. Rajan Bharti Mittal were re-appointed as Independent Directors, receiving 99.64% and 99.65% of votes in favor, respectively. Furthermore, Ms. Shonan Purie Trehan was appointed as a Non-Executive Non-Independent Director with 99.82% approval. The high participation and near-unanimous voting from institutional and public shareholders reflect strong confidence in the company's governance.

Resolution for Dr. Ravi Gupta's re-appointment passed with 99.6383% votes in favor.
Mr. Rajan Bharti Mittal's re-appointment as Independent Director secured 99.6517% approval.
Appointment of Ms. Shonan Purie Trehan as Non-Executive Director passed with 99.8236% support.
Total valid votes cast amounted to 24,12,94,677, representing high shareholder engagement across promoter and public categories.

💡 The overwhelming support for these appointments indicates strong institutional trust in Medanta's leadership. Investors can remain confident in the company's stable governance and continuity of its strategic direction.

Medanta Schedules One-on-One Investor Meeting with HSBC Securities on March 17

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 11 Mar 2026, 06:13 PM

Global Health Limited (Medanta) has announced a one-on-one meeting with HSBC Securities and Capital Markets (India) Private Limited. The meeting is scheduled for March 17, 2026, and will be conducted in person at Noida. This is a routine regulatory filing under SEBI (LODR) Regulations, 2015. The company has explicitly stated that no unpublished price sensitive information (UPSI) will be shared during the session.

One-on-one meeting scheduled with HSBC Securities on March 17, 2026.
The meeting will be held in person at Noida.
Compliance with Regulation 30 of SEBI (LODR) Regulations, 2015.
Company confirms no unpublished price sensitive information (UPSI) will be shared.

💡 No immediate action is required as this is a standard institutional interaction. Investors may look for any subsequent investor presentations that might be uploaded to the exchanges.

Medanta to Meet Institutional Investors in Gurugram on March 16, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 06 Mar 2026, 07:10 PM

Global Health Limited (Medanta) has announced a group meeting with institutional investors and analysts scheduled for March 16, 2026. The meeting is being organized by Goldman Sachs and will be held in person at Gurugram. The company has explicitly stated that no unpublished price-sensitive information (UPSI) will be shared during this interaction. This event is part of Medanta's routine investor relations activities to maintain transparency with the financial community.

Group meeting with analysts and institutional investors scheduled for March 16, 2026.
The meeting is organized by Goldman Sachs and will be conducted in person in Gurugram.
Compliance disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Company confirmed that no Unpublished Price Sensitive Information (UPSI) will be disclosed.

💡 No immediate action is required as this is a routine corporate disclosure. Investors should watch for any investor presentations or transcripts that may be released following the meeting for insights into the company's growth strategy.

Medanta Schedules One-on-One Investor Meeting for February 27, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 19 Feb 2026, 05:48 PM

Global Health Limited (Medanta) has announced a one-on-one meeting with institutional investors scheduled for February 27, 2026. The meeting will be held in person at Gurugram and is being organized by BofA Securities India Limited. The company has clarified that no unpublished price sensitive information (UPSI) will be shared during this interaction. This is a standard regulatory disclosure in compliance with SEBI (LODR) Regulations, 2015.

One-on-one meeting with institutional investors scheduled for February 27, 2026.
The meeting is organized by BofA Securities India Limited.
Interaction will take place in person in Gurugram.
Company confirms that no unpublished price sensitive information will be shared.

💡 This is a routine investor relations update and requires no immediate action. Investors may monitor the company's website for any post-meeting presentations or transcripts if they become available.

Medanta Schedules Institutional Investor Meetings from February 24 to 26, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 17 Feb 2026, 06:06 PM

Global Health Limited (Medanta) has announced a series of upcoming interactions with institutional investors and analysts. The management will participate in the Kotak India Conference on February 24 and IIFL's 17th Enterprising India Global Investors' Conference on February 25, both in Mumbai. Additionally, a group meeting with Kotak Securities is scheduled for February 26 in Gurugram. These meetings are intended to discuss the company's growth trajectory and business outlook in one-to-one and group formats.

Participation in Kotak India Conference: Chasing Growth 2026 on February 24 in Mumbai.
Attendance at IIFL's 17th Enterprising India Global Investors' Conference on February 25 in Mumbai.
Scheduled group meeting with Kotak Securities on February 26 in Gurugram.
Meetings will be conducted in person and include both one-to-one and group interaction modes.
Company confirmed that no Unpublished Price Sensitive Information (UPSI) will be shared during these meets.

💡 No immediate action is required as this is a routine corporate disclosure. Investors should watch for any investor presentations or management transcripts that may be released following these conferences.

View All MEDANTA Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Matured hospitals (Gurugram, Indore, Ranchi) grew 10.6% YoY to INR 26,119 million in FY25; Developing hospitals (Lucknow, Patna) grew 10% YoY to INR 10,940 million. Outpatient pharmacy revenue increased 26% from INR 1,120 million to INR 1,400 million. International patient revenue grew 7.8% in FY25 and surged 49% YoY in Q2 FY26 to INR 762 million.

Geographic Revenue Split

Revenue is diversified across 5 states. Matured facilities (Gurugram, Indore, Ranchi) contribute approximately 70.5% of healthcare services revenue, while developing facilities (Lucknow, Patna) contribute 29.5%. International patients account for approximately 5.5% of total revenue in FY25.

Profitability Margins

Consolidated PAT margin was 12.8% in FY25. In Q2 FY26, PAT margin improved to 14.2% from 13.4% YoY. Standalone profitability declined 5.1% due to one-time merger provisioning, while consolidated PAT grew 0.68% in FY25 to INR 4,813.18 million.

EBITDA Margin

Consolidated EBITDA margin was 25.4% in FY25 (INR 9,561.6 million), down from 26.1% YoY. Q2 FY26 EBITDA margin (ex-Noida) was 25.2%, while including Noida startup losses, the margin was 23.3% (INR 2,607 million).

Capital Expenditure

H1 FY26 capex was INR 4,252 million. Total planned project capex is estimated at INR 36,700 million for 2,000 additional beds. Maintenance capex is projected at INR 4,500 million over the next three years. The Noida project cost was revised upward to INR 15,300 million to accommodate 750 beds.

Credit Rating & Borrowing

CRISIL A+/Positive rating for major subsidiaries. Interest coverage ratio improved to 10.5 times in fiscal 2024 from 7.83 times. Debt-to-Equity ratio improved to 0.10x in FY25 from 0.14x following debt repayment.

⚙️ Operational Drivers

Raw Materials

Medical consumables, pharmaceuticals, and surgical implants represent the primary variable costs, though specific % of total cost is not disclosed. Employee benefits (doctors/nurses) are a major cost driver with 11,800+ staff.

Import Sources

Not specifically disclosed, but medical equipment like the 128-slice Dual Source CT and MAGNETOM Altea 1.5 Tesla MRI are sourced from global medical technology providers.

Key Suppliers

Partnerships include US-based firms for DOCBOX cardiac monitoring and Qure.ai for AI-powered imaging decision support.

Capacity Expansion

Current capacity includes 57 new beds added at Patna in H1 FY26. Planned expansion of 1,000 beds across Noida, Lucknow, Patna, and Ranchi, plus 2,000 beds via greenfield projects in Mumbai (Oshiwara), Pitampura (Delhi), and Guwahati (Assam) over 3-4 years.

Raw Material Costs

Inventory turnover improved to 13.13x in FY25 from 11.94x, indicating more efficient management of medical supplies and pharmacy stock.

Manufacturing Efficiency

Occupancy stood at ~64% in Q2 FY26 on increased bed capacity. ARPOB (Average Revenue Per Occupied Bed) grew 5.5% YoY to INR 65,570, reflecting better case mix and realization.

Logistics & Distribution

Not disclosed as a % of revenue; however, the company operates hospital-based and retail outpatient pharmacies which grew 26% in revenue.

📈 Strategic Growth

Expected Growth Rate

15%

Growth Strategy

Growth will be driven by adding 2,000 beds through greenfield projects in Mumbai, Delhi, and Guwahati, and scaling the 750-bed Noida facility. The company is also increasing its international patient reach (49% growth in Q2 FY26) and expanding its outpatient pharmacy and digital health (AI/predictive analytics) offerings.

Products & Services

Tertiary and quaternary healthcare services specializing in Cardiac Sciences, Oncology, Gastroenterology, Neurosciences, and Renal Sciences/Urology, which contribute 65.8% of revenue.

Brand Portfolio

Medanta, Global Health Limited, Medanta The Medicity.

New Products/Services

Launch of Medanta Noida in September 2025 (INR 39 million revenue in month one). New AI-powered services like DOCBOX and Qure.ai imaging support are expected to enhance clinical outcomes.

Market Expansion

Expansion into Mumbai (Oshiwara), Pitampura (Delhi), and Guwahati (Assam) with large-format greenfield hospitals over the next 3-4 years.

Market Share & Ranking

Not specifically ranked by %, but described as a 'trusted leader' and 'destination for high-end tertiary care' in North and East India.

Strategic Alliances

Collaborations with the UP state government for 'Mission TB-Free' and partnerships with US-based firms for cardiac critical care monitoring systems.

🌍 External Factors

Industry Trends

The industry is shifting toward digital health and AI integration. Medanta is positioning itself by adopting AI-powered imaging and next-gen cardiac monitoring to maintain its 'destination care' status.

Competitive Landscape

Faces competition from other private hospital chains in metro areas, which risks talent poaching and pressure on occupancy rates.

Competitive Moat

Moat is built on 'Clinical Excellence' and a 'Doctor-led' model. The brand reputation for complex quaternary care (65.8% revenue from top 5 specialties) and high-end infrastructure makes it difficult for new entrants to replicate.

Macro Economic Sensitivity

Highly sensitive to healthcare spending trends and insurance penetration. Growing demand for high-quality healthcare in underserved regions like Patna and Lucknow drives the 10% growth in developing hospitals.

Consumer Behavior

Shift toward seeking 'destination care' for complex surgeries, benefiting Medanta's high-end tertiary model.

Geopolitical Risks

Medical value travel (international patients) is subject to geopolitical stability and visa regulations, impacting the 5.5% revenue share from this segment.

⚖️ Regulatory & Governance

Industry Regulations

Compliance with the Companies Act 2013, SEBI Listing Regulations, and healthcare-specific standards for clinical excellence and patient safety.

Environmental Compliance

ESG oversight is managed by the Board; initiatives include the 'TB-Free Uttar Pradesh' campaign and early breast cancer detection programs.

Taxation Policy Impact

Effective tax rate resulted in tax expenses of INR 1,659.39 million on PBT of INR 6,472.57 million (approx 25.6%) in FY25.

Legal Contingencies

The company monitors brand equity risks related to legal non-compliance or patient dissatisfaction; specific pending case values are not disclosed in the provided text.

⚠️ Risk Analysis

Key Uncertainties

Expansion risk: Delays in constructing the 2,000-bed pipeline could impact projected returns. People risk: High turnover of skilled professionals could damage brand reputation.